Back to search

Article

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries

2022-03-28

Abstract excerpt

<h4>Background: </h4> Despite the increased utilisation of Managed Entry Agreements (MEAs), empirical studies assessing their impact on achieving better access to medicines remains scarce. In this study we evaluated the role of MEAs on enhancing availability of and timely access to a sample of oncology medicines that had received at least one prior rejection from reimbursement. <h4>Methods: </h4>: Funding decision...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
29649a1b-bcac-50aa-8368-213048642f01
DOI
10.21203/rs.3.rs-1471673/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countriesDOI 10.21203/rs.3.rs-1471673/v1
Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity
The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity
Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity
The uptake of best-value medicines across England -- a mixed method studySemantic proximity
How cancer patients perceive clinical trials (CTs) in the era of CTs: <i>Current perceptional status and differences between common and rare cancers</i>Semantic proximity
Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in BrazilSemantic proximity
Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity
PREFER-DMT: A Discrete Choice Experiment Framework for Eliciting Stakeholder Preferences on Disease-Modifying Therapy Implementation in European Healthcare SystemsSemantic proximity
Operationalisation of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure – timelines to recommendation and national registration decisionsSemantic proximity
The clinician impact and financial cost to the NHS of litigation over pregabalin: a cohort study in English primary careSemantic proximity
Select a neighboring publication to make it the new centre.